European Journal of Heart Failure
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Flexible vs. fixed diuretic regimen in the management of advanced chronic heart failure: study protocol for a pilot randomized control trial
2023
-
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial
2022
-
Anti-thymocyte globulin induction therapy usage is not associated with short and long-term survival differences in heart transplant patients
2019
-
Hypertrophic cardiomyopathy unmasked after treatment of heart failure
2019
-
Pulmonary hypertension and left atrial enlargement are associated with blunting of reduction in hospital resource utilization in patients enrolled in specialty heart failure clinic
2019
-
The impact of ischemic time and procurement distance on long-term survival following heart transplantation in a tertiary care center: 30 years of experience
2019
-
Starting with the patient: designing an electronic application with patient and caregiver feedback to promote heart failure self-care in the home setting
2018
-
Can serum prolactin level determine the severity of acute decompensated heart failure?
2017
-
Increases in natriuretic peptides precede heart failure hospitalization in patients with a recent coronary event and type 2 diabetes
2017
-
Pulmonary hypertension in end-stage renal disease patients undergoing haemodialysis via arterio-venous access
2017
-
Global variations in heart failure outcomes: INTER-CHF
2016
-
Increasing incidence of cardiomyopathy among women between the last trimester and the first 6 months post delivery
2015
-
A Prediction Model for Sudden Cardiac Death in Patients With Heart Failure and Preserved Ejection Fraction
2014
-
Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme
2013
-
Recent prior heart failure hospitalization is associated with risk of clinical events in patients with reduced and preserved ejection fraction in the CHARM trials
2013
-
Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE‐I, European CRT survey, German pre‐SCD II registry, and MADIT‐CRT
2009
-
Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial..
27:285-292.
2025
-
Long-term clinical outcomes and healthcare resource utilization in male and female patients following hospitalization for heart failure..
27:377-387.
2025
-
The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study.
2024
-
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria.
26:1369-1380.
2024
-
Effect of a transitional care model following hospitalization for heart failure: 3‐year outcomes of the Patient‐Centered Care Transitions in Heart Failure (PACT‐HF) randomized controlled trial.
26:652-660.
2024
-
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP‐HF II trial.
26:177-189.
2024
-
A scoping review of heart failure transitional care quality indicators and outcomes for use in clinical care and research.
25:1842-1848.
2023
-
Artificial intelligence and heart failure: A state‐of‐the‐art review.
25:1507-1525.
2023
-
Sex differences in long‐term outcomes following acute heart failure hospitalization: Findings from the Get With The Guidelines‐Heart Failure registry.
25:1544-1554.
2023
-
Patient‐reported outcome measures and patient engagement in heart failure clinical trials: multi‐stakeholder perspectives.
25:478-487.
2023
-
Reply to the letter regarding the article ‘Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial’.
24:2207-2208.
2022
-
Distinct pathophysiological pathways in women and men with heart failure.
24:1532-1544.
2022
-
Factors associated with health‐related quality of life in heart failure in 23 000 patients from 40 countries: results of the G‐CHF research programme.
24:1478-1490.
2022
-
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
23:1698-1707.
2021
-
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial.
23:1488-1498.
2021
-
Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?.
23:1437-1444.
2021
-
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review.
23:15-24.
2021
-
The impact of palliative care on clinical and patient‐centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials.
22:2340-2346.
2020
-
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome.
22:1133-1143.
2020
-
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
21:998-1007.
2019
-
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.
21:974-984.
2019
-
Impact of exercise‐based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta‐analysis of randomised trials.
20:1735-1743.
2018
-
Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
20:1230-1239.
2018
-
Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
20:504-510.
2018
-
Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.
20:295-303.
2018
-
Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta‐analysis.
19:1427-1443.
2017
-
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme.
18:1508-1517.
2016
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non‐vitamin K antagonist oral anticoagulant dose adjustment.
18:1162-1171.
2016
-
Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial.
18:1021-1031.
2016
-
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
17:925-935.
2015
-
Changes in N‐terminal pro‐B‐type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I‐Preserve study.
17:809-817.
2015
-
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
17:196-204.
2015
-
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
17:169-176.
2015
-
A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction.
16:1175-1182.
2014
-
Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve).
16:778-787.
2014
-
Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved’ [Eur J Heart Fail 2014;16:33–40].
16:592-592.
2014
-
Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
16:325-333.
2014
-
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved.
16:33-40.
2014
-
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial.
15:1053-1061.
2013
-
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme.
12:738-745.
2010
-
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.
12:557-565.
2010
-
Adherence to medication according to sex and age in the CHARM programme.
11:1092-1098.
2009
-
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
11:170-177.
2009
-
BNP and NT‐proBNP predict echocardiographic severity of diastolic dysfunction.
10:252-259.
2008
-
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial.
10:157-163.
2008
-
Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial.
10:149-156.
2008
-
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.
10:125-128.
2008
-
Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme.
9:510-517.
2007
-
Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
9:83-91.
2007
-
Corrigendum to “Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta‐analysis” [Eur J Heart Fail 7 (2005) 1133—1144].
8:223-224.
2006
-
Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta‐analysis.
8:90-96.
2006
-
Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta‐analysis.
7:1133-1144.
2005
-
Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice.
7:710-721.
2005
-
A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non‐ischaemic origin.
7:557-565.
2005
-
Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
7:650-656.
2005
-
Instruments to measure acceptability of information and acquisition of knowledge in patients with heart failure.
5:783-791.
2003
-
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme.
5:261-270.
2003
-
Interobserver reliability and validity of the New York Heart Association Functional Classification (NYHA‐FC) in heart failure patients.
2:73-74.
2000
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)